{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:29:51Z","timestamp":1785569391776,"version":"3.56.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T00:00:00Z","timestamp":1375488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T00:00:00Z","timestamp":1375488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40265-013-0102-7","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T11:35:41Z","timestamp":1375443341000},"page":"1463-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"73","author":[{"given":"Paul L.","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,3]]},"reference":[{"issue":"4","key":"102_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180\u20138.","journal-title":"J Clin Invest."},{"issue":"9648","key":"102_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet."},{"issue":"2","key":"102_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","volume":"17","author":"H Lassmann","year":"2007","unstructured":"Lassmann H, Br\u00fcck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210\u20138.","journal-title":"Brain Pathol"},{"key":"102_CR4","unstructured":"The Merck Manual for health care professionals. Multiple sclerosis (MS). 2007. http:\/\/www.merckmanuals.com\/professional\/neurologic_disorders\/demyelinating_disorders\/multiple_sclerosis_ms.html#v1045059. Accessed 12 Jul 2013."},{"issue":"9313","key":"102_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221\u201331.","journal-title":"Lancet."},{"issue":"25","key":"102_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa067597","volume":"356","author":"C Renoux","year":"2007","unstructured":"Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603\u201313.","journal-title":"N Engl J Med."},{"issue":"Pt. 7","key":"102_CR7","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt. 7):1914\u201329.","journal-title":"Brain."},{"issue":"2","key":"102_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169\u201378.","journal-title":"Neurology"},{"issue":"1","key":"102_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1191\/1352458502ms769oa","volume":"8","author":"MS Freedman","year":"2002","unstructured":"Freedman MS, Blumhardt LD, Brochet B, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler. 2002;8(1):19\u201323.","journal-title":"Mult Scler."},{"issue":"17","key":"102_CR10","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.2165\/0003495-200868170-00004","volume":"68","author":"T Menge","year":"2008","unstructured":"Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445\u201368.","journal-title":"Drugs."},{"key":"102_CR11","unstructured":"European Medicines Agency. Tysabri (natalizumab): summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf. Accessed 12 Jul 2013."},{"issue":"1","key":"102_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11596920-000000000-00000","volume":"26","author":"H Gensicke","year":"2012","unstructured":"Gensicke H, Leppert D, Yaldizli O, et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs. 2012;26(1):11\u201337.","journal-title":"CNS Drugs."},{"key":"102_CR13","unstructured":"European Medicines Agency. Tysabri (natalizumab): summary of opinion (post authorisation). 2013. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000603\/smops\/Positive\/human_smop_000525.jsp&mid=WC0b01ac058001d127. Accessed 12 Jul 2013."},{"issue":"4","key":"102_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2567.2011.03549.x","volume":"135","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang H. Integrin signalling and function in immune cells. Immunology. 2012;135(4):268\u201375.","journal-title":"Immunology."},{"key":"102_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1471-2377-12-95","volume":"12","author":"C Oreja-Guevara","year":"2012","unstructured":"Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, et al. TH1\/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab. BMC Neurol. 2012;12:95.","journal-title":"BMC Neurol."},{"key":"102_CR16","unstructured":"Biogen Idec, Elan Pharmaceuticals. Tysabri (natalizumab) injection: US prescribing information. 2012. http:\/\/www.tysabri.com\/pdfs\/I61061-13_PI.pdf. Accessed 12 Jul 2013."},{"issue":"3","key":"102_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s00415-006-0356-z","volume":"254","author":"D Soon","year":"2007","unstructured":"Soon D, Altmann DR, Fernando KTM, et al. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol. 2007;254(3):306\u201314.","journal-title":"J Neurol."},{"issue":"5","key":"102_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"O St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743\u20137.","journal-title":"Ann Neurol."},{"issue":"10","key":"102_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","volume":"63","author":"O St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Bar-Or A, et al. Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383\u20137.","journal-title":"Arch Neurol."},{"key":"102_CR20","doi-asserted-by":"crossref","unstructured":"del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65(12):1596\u2013603.","DOI":"10.1001\/archneur.65.12.noc80051"},{"issue":"4","key":"102_CR21","doi-asserted-by":"publisher","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","volume":"7","author":"C de Andr\u00e9s","year":"2012","unstructured":"de Andr\u00e9s C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS ONE. 2012;7(4):e34103.","journal-title":"PLoS ONE."},{"issue":"1\u20132","key":"102_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","volume":"227","author":"A Millonig","year":"2010","unstructured":"Millonig A, Hegen H, Di Pauli F, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol. 2010;227(1\u20132):190\u20134.","journal-title":"J Neuroimmunol."},{"issue":"3","key":"102_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1468-1331.2007.02037.x","volume":"15","author":"M Khademi","year":"2008","unstructured":"Khademi M, Stol D, Olsson T, et al. Induction of systemic TNF\u03b1 in natalizumab-treated multiple sclerosis. Eur J Neurol. 2008;15(3):309\u201312.","journal-title":"Eur J Neurol."},{"issue":"22","key":"102_CR24","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","volume":"72","author":"P Kivis\u00e4kk","year":"2009","unstructured":"Kivis\u00e4kk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22):1922\u201330.","journal-title":"Neurology."},{"issue":"11","key":"102_CR25","doi-asserted-by":"publisher","first-page":"e47578","DOI":"10.1371\/journal.pone.0047578","volume":"7","author":"L B\u00f6rnsen","year":"2012","unstructured":"B\u00f6rnsen L, Christensen JR, Ratzer R, et al. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. PLoS ONE. 2012;7(11):e47578.","journal-title":"PLoS ONE."},{"issue":"12","key":"102_CR26","doi-asserted-by":"publisher","first-page":"e52208","DOI":"10.1371\/journal.pone.0052208","volume":"7","author":"TF Benkert","year":"2012","unstructured":"Benkert TF, Dietz L, Hartmann EM, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS ONE. 2012;7(12):e52208.","journal-title":"PLoS ONE."},{"issue":"17","key":"102_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, K\u00fcmpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71(17):1350\u20134.","journal-title":"Neurology."},{"issue":"3","key":"102_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201142108","volume":"42","author":"R Planas","year":"2012","unstructured":"Planas R, Jel\u010di\u0107 I, Schippling S, et al. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol. 2012;42(3):790\u20138.","journal-title":"Eur J Immunol."},{"issue":"1\u20132","key":"102_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jneuroim.2011.02.010","volume":"235","author":"M Skarica","year":"2011","unstructured":"Skarica M, Eckstein C, Whartenby KA, et al. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol. 2011;235(1\u20132):70\u20136.","journal-title":"J Neuroimmunol."},{"issue":"7","key":"102_CR30","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1182\/blood-2007-09-112052","volume":"111","author":"H Bonig","year":"2008","unstructured":"Bonig H, Wundes A, Chang K-H, et al. Increased numbers of circulating hematopoietic stem\/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111(7):3439\u201341.","journal-title":"Blood."},{"issue":"10","key":"102_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/bmt.2009.381","volume":"45","author":"D Jing","year":"2010","unstructured":"Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant. 2010;45(10):1489\u201396.","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"102_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/archneurol.2011.238","volume":"68","author":"C Saure","year":"2011","unstructured":"Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011;68(11):1428\u201331.","journal-title":"Arch Neurol."},{"issue":"Suppl","key":"102_CR33","first-page":"1","volume":"78","author":"B Cree","year":"2012","unstructured":"Cree B, De Seze J, Fox R, et al. RESTORE study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity [abstract]. Neurology. 2012;78(Suppl):1.","journal-title":"Neurology."},{"issue":"1","key":"102_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ana.22247","volume":"69","author":"M Gunnarsson","year":"2011","unstructured":"Gunnarsson M, Malmestr\u00f6m C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83\u20139.","journal-title":"Ann Neurol."},{"issue":"1","key":"102_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ane.12004","volume":"127","author":"H Schneider","year":"2013","unstructured":"Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy\u2014effects on the neonatal immune system. Acta Neurol Scand. 2013;127(1):e1\u20134.","journal-title":"Acta Neurol Scand."},{"issue":"5","key":"102_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","volume":"52","author":"WA Sheremata","year":"1999","unstructured":"Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999;52(5):1072\u20134.","journal-title":"Neurology"},{"issue":"5","key":"102_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"BO Khatri","year":"2009","unstructured":"Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402\u20139.","journal-title":"Neurology"},{"issue":"9","key":"102_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"9","key":"102_CR39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med"},{"key":"102_CR40","unstructured":"Biogen Idec, Elan Pharmaceuticals. Natalizumab re-initiation of dosing (ClinicalTrials.gov identifier NCT00306592) US National Institutes of Health, ClinicalTrials.gov. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00306592?term=natalizumab+AND+sclerosis&rank=18. Accessed 12 Jul 2013."},{"key":"102_CR41","unstructured":"Biogen Idec, Elan Pharmaceuticals. Natalizumab re-initiation of dosing (STRATA) [ClinicalTrials.gov identifier NCT00297232] US National Institutes of Health, ClinicalTrials.gov. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00297232?term=nct00297232&rank=1. Accessed 12 Jul 2013."},{"key":"102_CR42","unstructured":"Biogen Idec. TOP: IMA-06-02 tysabri obervational program (ClinicalTrials.gov identifier NCT00493298) US National Institutes of Health, ClinicalTrials.gov. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00493298?term=nct00493298&rank=1. Accessed 12 Jul 2013."},{"issue":"17","key":"102_CR43","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"DH Miller","year":"2007","unstructured":"Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390\u2013401.","journal-title":"Neurology."},{"issue":"3","key":"102_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254\u201360.","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"102_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jns.2012.03.009","volume":"318","author":"LJ Balcer","year":"2012","unstructured":"Balcer LJ, Galetta SL, Polman CH, et al. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. J Neurol Sci. 2012;318(1\u20132):119\u201324.","journal-title":"J Neurol Sci."},{"issue":"16","key":"102_CR46","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","volume":"68","author":"LJ Balcer","year":"2007","unstructured":"Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299\u2013304.","journal-title":"Neurology."},{"issue":"4","key":"102_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ana.21163","volume":"62","author":"RA Rudick","year":"2007","unstructured":"Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62(4):335\u201346.","journal-title":"Ann Neurol."},{"issue":"2","key":"102_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/01312067-200902020-00006","volume":"2","author":"SA Kamat","year":"2009","unstructured":"Kamat SA, Rajagopalan K, Stephenson JJ, et al. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey. Patient. 2009;2(2):105\u201312.","journal-title":"Patient."},{"issue":"5","key":"102_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/11593770-000000000-00000","volume":"25","author":"S Olofsson","year":"2011","unstructured":"Olofsson S, Wickstr\u00f6m A, H\u00e4ger Glenng\u00e5rd A, et al. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1\u00a0year of treatment. BioDrugs. 2011;25(5):299\u2013306.","journal-title":"BioDrugs."},{"issue":"10 Suppl. 1","key":"102_CR50","first-page":"S444","volume":"17","author":"A Goodman","year":"2011","unstructured":"Goodman A, O\u2019Connor P, Polman C, et al. Updated safety and efficacy of natalizumab in the ongoing STRATA study [abstract]. Mult Scler. 2011;17(10 Suppl. 1):S444\u20135.","journal-title":"Mult Scler."},{"key":"102_CR51","unstructured":"Polman C, Goodman A, Kappos L, et al. Efficacy and safety of natalizumab in the STRATA study [abstract no. P06.173]. 62nd Annual Meeting of the American Academy of Neurology; 10-17 Apr 2010; Toronto, ON."},{"issue":"10 Suppl. 1","key":"102_CR52","first-page":"S219","volume":"17","author":"R Rudick","year":"2011","unstructured":"Rudick R, Kappos L, Polman C, et al. Long-term outcomes in natalizumab-treated patients who were free of disease activity over the 2-year AFFIRM study [abstract]. Mult Scler. 2011; 17(10 Suppl. 1):S219\u201320.","journal-title":"Mult Scler"},{"issue":"Suppl","key":"102_CR53","first-page":"1","volume":"78","author":"L Kappos","year":"2012","unstructured":"Kappos L, Belachew S, Butzkueven H, et al. Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the Tysabri observational program (TOP) [abstract]. Neurology. 2012;78(Suppl):1.","journal-title":"Neurology."},{"issue":"1","key":"102_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJMc086089","volume":"359","author":"MA Panzara","year":"2008","unstructured":"Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359(1):99\u2013100.","journal-title":"N Engl J Med."},{"issue":"1","key":"102_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/archdermatol.2010.243","volume":"147","author":"E Castela","year":"2011","unstructured":"Castela E, Lebrun-Frenay C, Laffon M, et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol. 2011;147(1):72\u20136.","journal-title":"Arch Dermatol."},{"key":"102_CR56","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2010.04262.x","volume":"31","author":"S Bezabeh","year":"2010","unstructured":"Bezabeh S, Flowers CM, Kortepeter C, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31:1028\u201335.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"102_CR57","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1177\/1352458512441688","volume":"18","author":"PEH Jensen","year":"2012","unstructured":"Jensen PEH, Koch-Henriksen N, Sellebjerg F, et al. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler. 2012;18(10):1493\u20139.","journal-title":"Mult Scler."},{"issue":"6","key":"102_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1352458510394701","volume":"17","author":"C Holm\u00e9n","year":"2011","unstructured":"Holm\u00e9n C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17(6):708\u201319.","journal-title":"Mult Scler."},{"issue":"3","key":"102_CR59","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1352458510385508","volume":"17","author":"B Oliver","year":"2011","unstructured":"Oliver B, Fern\u00e1ndez O, Orpez T, et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18\u00a0months. Mult Scler. 2011;17(3):368\u201371.","journal-title":"Mult Scler."},{"issue":"Suppl. 3","key":"102_CR60","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1007\/s10072-010-0345-y","volume":"31","author":"F Piehl","year":"2011","unstructured":"Piehl F, Holm\u00e9n C, Hillert J, et al. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. 2011;31(Suppl. 3):S289\u201393.","journal-title":"Neurol Sci."},{"issue":"9","key":"102_CR61","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/1352458511404271","volume":"17","author":"PS S\u00f8rensen","year":"2011","unstructured":"S\u00f8rensen PS, Jensen PEH, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011;17(9):1074\u20138.","journal-title":"Mult Scler."},{"issue":"6","key":"102_CR62","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1177\/1352458512462920","volume":"19","author":"M Lundkvist","year":"2013","unstructured":"Lundkvist M, Engdahl E, Holm\u00e9n C, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler. 2013;19(6):757\u201364.","journal-title":"Mult Scler."},{"issue":"5","key":"102_CR63","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458512460604","volume":"19","author":"A Vennegoor","year":"2013","unstructured":"Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19(5):593\u2013600.","journal-title":"Mult Scler."},{"issue":"14","key":"102_CR64","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391\u2013403.","journal-title":"Neurology."},{"issue":"12","key":"102_CR65","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/archneur.65.12.1566","volume":"65","author":"B Becher","year":"2008","unstructured":"Becher B. Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch Neurol. 2008;65(12):1566\u20137.","journal-title":"Arch Neurol."},{"issue":"4","key":"102_CR66","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425\u201337.","journal-title":"Lancet Neurol."},{"issue":"8","key":"102_CR67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","volume":"10","author":"L Kappos","year":"2011","unstructured":"Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745\u201358.","journal-title":"Lancet Neurol."},{"issue":"20","key":"102_CR68","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med."},{"issue":"4","key":"102_CR69","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med. 2005;353(4):362\u20138.","journal-title":"N Engl J Med."},{"key":"102_CR70","unstructured":"Biogen Idec, Elan Corporation plc. New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status [media release]. 2013. http:\/\/www.biogenidec.com\/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1797077."},{"key":"102_CR71","unstructured":"Barts and The London School of Medicine and Dentistry. Mulitple sclerosis research: natalizumab-associated PML update: March 2013. 2013. http:\/\/multiple-sclerosis-research.blogspot.co.nz\/2013\/04\/natalizumab-associated-pml-update-march.html. Accessed 12 Jul 2013."},{"issue":"2","key":"102_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1756285612470401","volume":"6","author":"\u00d3 Fern\u00e1ndez","year":"2013","unstructured":"Fern\u00e1ndez \u00d3. Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(2):69\u201379.","journal-title":"Ther Adv Neurol Disord."},{"key":"102_CR73","unstructured":"Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients [abstract no. DX51 plus poster]. In: 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers; 29 May\u20131 Jun 2013; Orlando, FL."},{"key":"102_CR74","unstructured":"European Medicines Agency. Transatlantic workshop on drug-related progressive multifocal leukoencephalopathy (PML): workshop proceedings. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2011\/09\/WC500111562.pdf. Accessed 12 Jul 2013."},{"key":"102_CR75","unstructured":"Foley J. Natalizumab related PML: an evolving risk stratification paradigm [abstract no. S30.002]. In: 65th Annual Meeting of the American Academy of Neurology; 16-23 March 2013; San Diego, CA."},{"issue":"11","key":"102_CR76","doi-asserted-by":"publisher","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","volume":"8","author":"MR Perkins","year":"2012","unstructured":"Perkins MR, Ryschkewitsch C, Liebner JC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog. 2012;8(11):e1003014.","journal-title":"PLoS Pathog."},{"issue":"22","key":"102_CR77","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858\u201365.","journal-title":"Neurology."},{"issue":"3","key":"102_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.53.3.466","volume":"53","author":"N Tubridy","year":"1999","unstructured":"Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999;53(3):466\u201372.","journal-title":"Neurology"},{"issue":"2","key":"102_CR79","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archneurol.2010.257","volume":"68","author":"A Miravalle","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2):186\u201391.","journal-title":"Arch Neurol."},{"issue":"13 Pt. 2","key":"102_CR80","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008; 70(13 Pt. 2):1150\u20131.","journal-title":"Neurology"},{"issue":"5","key":"102_CR81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","volume":"19","author":"G Borriello","year":"2012","unstructured":"Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol. 2012;19(5):783\u20137.","journal-title":"Eur J Neurol."},{"issue":"3","key":"102_CR82","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ana.22083","volume":"68","author":"JR Berger","year":"2010","unstructured":"Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010;68(3):409\u201311.","journal-title":"Ann Neurol."},{"key":"102_CR83","unstructured":"Havla J, Tackenberg B, Hellwig K, et al. Early initiation of fingolimod treatment reduces the recurrence of disease activity after natalizumab discontinuation in multiple sclerosis [abstract no. P01.199 plus poster]. In: 65th Annual Meeting of the American Academy of Neurology; 16-23 Mar 2013; San Diego, CA."},{"key":"102_CR84","unstructured":"LaGanke CC, Cullman AL. Natalizumab exit strategy experience with fingolimod [abstract no. P01.206]. In: 65th Annual Meeting of the American Academy of Neurology; 16\u201323 Mar 2013; San Diego, CA."},{"key":"102_CR85","unstructured":"Cohen M, Maillart E, Papeix C, et al. ENIGM: a French observational study about switching from natalizumab to fingolimod in multiple sclerosis [abstract no. S41.002]. In: 65th Annual Meeting of the American Academy of Neurology; 16\u201323 Mar 2013; San Diego, CA."},{"issue":"2","key":"102_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF03256144","volume":"7","author":"SR Earnshaw","year":"2009","unstructured":"Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009;7(2):91\u2013108.","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"102_CR87","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri\u00ae) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617\u201327.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"102_CR88","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1352458507086667","volume":"14","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14(5):679\u201390.","journal-title":"Mult Scler."},{"issue":"8","key":"102_CR89","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1177\/1352458511401944","volume":"17","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958\u201363.","journal-title":"Mult Scler."},{"issue":"3","key":"102_CR90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1586\/ern.13.12","volume":"13","author":"E Lu","year":"2013","unstructured":"Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13(3):251\u201360.","journal-title":"Expert Rev Neurother."},{"key":"102_CR91","unstructured":"National Collaborating Centre for Chronic Conditions. Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care (NICE Clinical Guideline, No. 8). 2004. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK48919\/pdf\/TOC.pdf. Accessed 12 Jul 2013."},{"key":"102_CR92","unstructured":"Association of British Neurologists. Revised (2009) Association of British Neurologists\u2019 guidelines for prescribing in multiple sclerosis. 2009. http:\/\/www.theabn.org\/abn\/userfiles\/file\/abn_ms_guidelines_2009_final.pdf. Accessed 12 Jul 2013."},{"key":"102_CR93","unstructured":"National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease management concensus statement about use of current disease-modifying agents. 2008. http:\/\/www.nationalmssociety.org\/ms-clinical-care-network\/clinical-resources-and-tools\/publications\/expert-opinion-papers\/index.aspx. Accessed 12 Jul 2013."},{"issue":"6","key":"102_CR94","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(09)70082-1","volume":"8","author":"RA Rudick","year":"2009","unstructured":"Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545\u201359.","journal-title":"Lancet Neurol."},{"issue":"8","key":"102_CR95","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","volume":"25","author":"LJ Scott","year":"2011","unstructured":"Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(8):673\u201398.","journal-title":"CNS Drugs."},{"issue":"5","key":"102_CR96","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med."},{"issue":"5","key":"102_CR97","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med."},{"key":"102_CR98","unstructured":"European Medicines Agency. Gilenya (fingolimod): summary of product characteristics. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002202\/WC500104528.pdf. Accessed 12 Jul 2013."},{"key":"102_CR99","unstructured":"European Medicines Agency. Gilenya (fingolimod): EPAR summary for the public. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002202\/WC500104530.pdf. Accessed 12 Jul 2013."},{"issue":"7","key":"102_CR100","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-013-0030-6","volume":"73","author":"R Ali","year":"2013","unstructured":"Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs. 2013;73(7):625\u201350.","journal-title":"Drugs."},{"issue":"12","key":"102_CR101","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med."},{"issue":"12","key":"102_CR102","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med."},{"key":"102_CR103","unstructured":"European Medicines Agency. Tecfidera (dimethyl fumarate): summary of opinion (initial authorisation). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002601\/WC500140695.pdf. Accessed 12 Jul 2013."},{"key":"102_CR104","unstructured":"European Medicines Agency. Aubagio (teriflunomide): summary of opinion (initial authorisation). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002514\/WC500140690.pdf. Accessed 12 Jul 2013."},{"issue":"11","key":"102_CR105","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1177\/1352458512450354","volume":"18","author":"AE Miller","year":"2012","unstructured":"Miller AE, O\u2019Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012;18(11):1625\u201332.","journal-title":"Mult Scler."},{"issue":"11","key":"102_CR106","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000\u20139.","journal-title":"N Engl J Med."},{"key":"102_CR107","unstructured":"Vollmer TL, Soelberg Sorensen P, Arnold DL, et al. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis [abstract no. 148]. In: 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; 19\u201322 Oct 2011; Amsterdam."},{"issue":"9856","key":"102_CR108","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819\u201328.","journal-title":"Lancet."},{"issue":"9856","key":"102_CR109","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet."},{"issue":"9884","key":"102_CR110","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","volume":"381","author":"R Gold","year":"2013","unstructured":"Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167\u201375.","journal-title":"Lancet."},{"issue":"9805","key":"102_CR111","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779\u201387.","journal-title":"Lancet."},{"issue":"10","key":"102_CR112","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1177\/1352458512439119","volume":"18","author":"H Tremlett","year":"2012","unstructured":"Tremlett H, Zhu F, Petkau J, et al. Natural, innate improvements in multiple sclerosis disability. Mult Scler. 2012;18(10):1412\u201321.","journal-title":"Mult Scler."},{"issue":"13","key":"102_CR113","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2165\/11538000-000000000-00000","volume":"70","author":"J Sharac","year":"2010","unstructured":"Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70(13):1677\u201391.","journal-title":"Drugs."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-013-0102-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0102-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:15:21Z","timestamp":1715814921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-013-0102-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,3]]},"references-count":113,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0102-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,3]]},"assertion":[{"value":"3 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}